HGS Execs Hid Lupus Drug's Suicide Link: Suit

Law360, New York (December 22, 2011, 6:12 PM EST) -- A Human Genome Sciences Inc. shareholder lodged a derivative complaint Wednesday against the biotech company's CEO and several other officers and directors, alleging they hid from investors the fact that lupus drug Benlysta caused an elevated rate of suicide among users.

In a complaint filed in Maryland federal court, plaintiff Edward L. Forgione Jr. alleges Human Genome CEO H. Thomas Watkins and the rest of the company's management broke their fiduciary duties to shareholders and wasted corporate assets by failing to disclose disturbing side effects found...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Forgione v. Watkins et al


Case Number

8:11-cv-03680

Court

Maryland

Nature of Suit

Stockholders Suits

Judge

Roger W Titus

Date Filed

December 20, 2011

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.